甲骨文董事长大力宣扬AI驱动mRNA疫苗，Moderna等个股应声走高_老虎社区_美港股上老虎

甲骨文董事长大力宣扬AI驱动mRNA疫苗，Moderna等个股应声走高

智通财经2025-01-23

1月23日，在甲骨文董事长Larry Ellison强调人工智能(AI)在开发mRNA癌症疫苗方面的潜力后，Moderna(MRNA.US)成为周三美股涨幅引人注目的股票之一。数据显示，Moderna周三收涨7.27%，报38.50美元/股。与此同时，以人工智能为重点的药物开发商也随之走高，AbCellera Biologics(ABCL.US)收涨15.36%，Absci(ABSI.US)收涨...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2505860540?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","is_english":false,"pubTime":"2025-01-23 08:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505860540","market":"us","top_or_hot":-1,"title":"甲骨文董事长大力宣扬AI驱动mRNA疫苗，Moderna等个股应声走高","media":"智通财经","content":"<div>\n<p>1月23日，在甲骨文董事长Larry Ellison强调人工智能(AI)在开发mRNA癌症疫苗方面的潜力后，Moderna(MRNA.US)成为周三美股涨幅引人注目的股票之一。数据显示，Moderna周三收涨7.27%，报38.50美元/股。与此同时，以人工智能为重点的药物开发商也随之走高，AbCellera Biologics(ABCL.US)收涨15.36%，Absci(ABSI.US)收涨...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1242279.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>甲骨文董事长大力宣扬AI驱动mRNA疫苗，Moderna等个股应声走高</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n甲骨文董事长大力宣扬AI驱动mRNA疫苗，Moderna等个股应声走高\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-23 08:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1242279.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月23日，在甲骨文董事长Larry Ellison强调人工智能(AI)在开发mRNA癌症疫苗方面的潜力后，Moderna(MRNA.US)成为周三美股涨幅引人注目的股票之一。数据显示，Moderna周三收涨7.27%，报38.50美元/股。与此同时，以人工智能为重点的药物开发商也随之走高，AbCellera Biologics(ABCL.US)收涨15.36%，Absci(ABSI.US)收涨...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1242279.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1242279.html","article_id":"2505860540","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505860540","pubTimestamp":1737592531,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，在甲骨文董事长Larry Ellison强调人工智能在开发mRNA癌症疫苗方面的潜力后，Moderna成为周三美股涨幅引人注目的股票之一。数据显示，Moderna周三收涨7.27%，报38.50美元/股。Moderna在2024年与OpenAI达成合作，在其业务中部署了人工智能公司ChatGPT Enterprise，旨在加速药物开发。Moderna与默沙东合作开发的个性化癌症疫苗mRNA-4157目前正处于针对皮肤癌黑色素瘤患者的后期开发阶段。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MRNA":"Moderna, Inc.","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","ABSI":"Absci Corporation.","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","ABCL":"AbCellera Biologics","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU1935042488.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC","BK4139":"生物科技","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","TEM":"Tempus AI","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","SDGR":"Schrodinger Inc.","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU1935043536.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC A","LU1935043023.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (USD) INC A","LU0444973449.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"DU\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0476273544.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"BU\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU1815336760.USD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"AUP\" (USD) INC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","BK4588":"碎股","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","LU0444971666.USD":"天利全球科技基金","DNA":"Ginkgo Bioworks Holdings Inc.","BK4548":"巴美列捷福持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","RXRX":"Recursion Pharmaceuticals, Inc.","BK4501":"段永平概念","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4551":"寇图资本持仓","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0056508442.USD":"贝莱德世界科技基金A2","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4543":"AI","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H"},"translate_title":"Oracle chairman vigorously promotes AI-driven mRNA vaccine, and Moderna and other stocks rise in response","themeId":"eb4b71ab88b390e88388adc7f9f221be","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/abe4a353f4a8ea5f3a24b4889aaa7e07","symbols_score_info":{"RXRX":1.1,"MRNA":1,"DNA":1.1,"TEM":1.1,"ABCL":1,"SDGR":1.1,"ABSI":1.1},"content_text":"1月23日，在甲骨文董事长Larry Ellison强调人工智能(AI)在开发mRNA癌症疫苗方面的潜力后，Moderna(MRNA.US)成为周三美股涨幅引人注目的股票之一。数据显示，Moderna周三收涨7.27%，报38.50美元/股。与此同时，以人工智能为重点的药物开发商也随之走高，AbCellera Biologics(ABCL.US)收涨15.36%，Absci(ABSI.US)收涨25.16%，Schrodinger(SDGR.US)收涨14.11%，Ginkgo Bioworks(DNA.US)收涨11.40%，Tempus AI(TEM.US)收涨5.90%，Recursion Pharmaceuticals(RXRX.US)收涨8.87%。Larry Ellison表示，人工智能可用于开发基于mRNA的个性化癌症疫苗和早期肿瘤检测。他解释称，人工智能可以用来分析旨在识别血液中循环的微小肿瘤碎片的测试，在对癌变分子进行基因测序后，个体化的癌症疫苗可以在大约两天内开发出来。他表示：“一旦我们对癌症肿瘤进行基因测序，你就可以为每个人设计一种疫苗，让他们接种疫苗来对抗这种癌症。你可以在大约48小时内用人工智能机器人制造这种mRNA疫苗。”Moderna在2024年与OpenAI达成合作，在其业务中部署了人工智能公司ChatGPT Enterprise，旨在加速药物开发。Moderna与默沙东(MRK.US)合作开发的个性化癌症疫苗mRNA-4157目前正处于针对皮肤癌黑色素瘤患者的后期开发阶段。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":3,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}